Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Net Loss per Common Share (Tables)

Net Loss per Common Share (Tables)

9 Months Ended

Sep. 30, 2016

Computations of Diluted Weighted Average Shares Outstanding

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive at the end of the nine months ended September 30, 2016 and 2015:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Warrants to purchase Common Stock		392,731		685,061		480,559		685,061
Opus warrants to purchase Common Stock		1,700,000		-		1,700,000		-
Options to purchase Common Stock		1,761,032		1,832,499		1,769,426		2,019,219
Unvested Restricted Stock		8,705,136		6,884,631		8,763,797		6,795,132
Unvested Restricted Stock Units		1,085,468		752,761		1,054,091		258,242
Total		13,644,367		10,154,952		13,767,873		9,757,654